Pneumococcal polysaccharide vaccine. Recommendation of the Immunization Practices Advisory Committee.
The risk of pneumococcal infection differs in different age ranges; the risk and the severity of the infection increases in persons with certain chronic diseases. Penicillin remains the best antimicrobial agent for treatment. The recently developed pneumococcal polysaccharide vaccine represents 14 serotypes responsible for a large majority of pneumococcal infections in the United States. The efficacy of the vaccine has been demonstrated in a number of trials. this vaccine recommendation statement indicates the persons most likely to benefit from vaccination and reviews the adverse effects likely to occur and the precautions to be taken in administering the vaccine.
D000328:Adult; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage*; D012306:Risk; D014481:United States; D014611:Vaccination
D001428:Bacterial Vaccines; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial